Talvy | $2,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)
Advocacy | $3,500,000 | (Mar 10, 2026)